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Abstract
Objective Genetic polymorphisms that modify the detox-
ifying activity of glutathione S-transferases (GSTs) can
affect the level of carcinogenic metabolites created by
endogenous steroid hormones and exogenous chemical
substances. Although the GSTM1 null genotype has been
shown to increase prostate cancer mortality in Caucasians,
potential associations between GST polymorphisms and
prostatecancerbiochemicalrecurrence(BCR)havenotbeen
well studied, particularly in African-Americans.
Methods We examined potential associations between the
GSTM1 null, GSTT1 null and GSTP1 Ile105Val poly-
morphisms and BCR, after prostatectomy, in 168 African-
American and 226 Caucasian patients treated at Henry Ford
Hospital in Detroit, Michigan using Cox proportional haz-
ards modeling.
Results We found that African-Americans with the
GSTT1 null genotype had increased BCR risk compared to
those having GSTT1 present (hazard ratio (HR) = 2.30;
95% CI = 1.01–5.18; p = 0.04); and African-Americans
with the GSTT1null genotypeand highgrade tumors hadan
even greater risk (HR = 7.82; 95% CI = 2.49–24.50;
p\0.001). In Caucasians, an increased risk was observed
in those patients with high grade tumors and the GSTM1
null genotype (HR = 2.88; 95% CI = 1.16–7.14; p =
0.02). Similar associations were observed for advanced
stage and more aggressive (high grade or advanced stage)
disease.
Conclusion Our results suggest GSTs may hold promise
as therapeutic targets in more advanced prostate cancers,
particularly, in African-Americans.
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Introduction
Prostate cancer is the most commonly diagnosed non-skin
cancer and the third leading cause of cancer death among
men in the United States [1], with higher mortality rates
among African-Americans compared to Caucasians [2].
Clinical diagnostic characteristics also affect prostate can-
cer mortality and biochemical recurrence rates. Those men
present with a biopsy Gleason score of eight or greater,
clinical tumor stage of T2c or greater, or serum prostate
speciﬁc antigen (PSA) level of greater than 20 ng/ml are at
high risk of disease recurrence [3] and mortality [4] even
after radical prostatectomy, while men with a Gleason score
of less than seven, tumor stage of T2a or less, or PSA of less
than 10 ng/ml are unlikely to die from prostate cancer [5].
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DOI 10.1007/s10552-009-9385-0Furthermore, compared to Caucasians with similar clinical
presentation, African-American men continue to show
higher rates of biochemical recurrence after prostatectomy
[6], suggesting other genetic and/or environmental factors
contribute to prostate cancer recurrence and mortality.
Glutathione S-transferases (GSTs) are an important
family of enzymes involved in the biosynthesis and
metabolism of many substances [7] including the detoxi-
ﬁcation of exogenous carcinogenic chemicals such as
polycyclic aromatic hydrocarbons (PAH), which are found
in many common exposures such as cigarette smoke,
diesel fuel and grilled meats. GSTs may also detoxify
reactive endogenous steroid hormone metabolites such as
estradiol (E2)-quinones and reactive oxygen species
(ROS), which may arise from multiple sources including
inﬂammation and the futile redox cycling of E2- and
PAH-quinones [8, 9]. Speciﬁc GST isoforms in the l
(M1), h (T1) and p (P1) classes are highly expressed in
the prostate [10, 11]; therefore, genetic polymorphisms
that modify activity of these GSTs can affect the level of
carcinogenic metabolites in the prostate, which, in turn,
may alter the risk of prostate cancer recurrence and
mortality as well as its incidence.
Functional genetic variants in GSTs, predominantly the
GSTM1 null, GSTT1 null and GSTP1 Ile105Val poly-
morphisms, have been associated inconsistently with
prostate cancer incidence; and authors of a recent meta-
analysis concluded that the GSTM1 null, GSTT1 null and
GSTP1 Ile105Val polymorphisms were unlikely to be
major determinants of prostate cancer susceptibility on a
wide population basis [12]. However, this meta-analysis
was conducted using Caucasian and Asian populations only
and did not include any studies with subjects of African
descent. This is a critical point because we have previously
shown that allele frequencies and associations between
GST polymorphisms and PAH-DNA adduct levels are
signiﬁcantly different among African-American compared
to Caucasian men [13]. Furthermore, the GSTM1-null
genotype has been shown to increase risk of prostate cancer
mortality in Caucasian men [14]; however, no prior studies
have examined potential effects of these GST polymor-
phisms on prostate cancer biochemical recurrence risk in
African-American men.
Therefore, we examined the potential associations
between the GSTM1-null, GSTT1-null and GSTP1
Ile105Val polymorphisms and prostate cancer biochemi-
cal recurrence within 5 years after prostatectomy surgery
in 168 African-American and 226 Caucasian patients
treated at the Henry Ford Hospital in Detroit, Michigan.
We also evaluated potential differential associations
between these GST polymorphisms and prostate cancer
BCR by ethnicity and clinical measures of disease
severity at diagnosis.
Materials and methods
Study population
The study population from which the subjects used in this
analysis were derived has been previously described [15].
Brieﬂy, 637 cases with a histologically conﬁrmed prostate
cancer diagnosis within the last 2 years that were treated at
the Henry Ford Hospital in Detroit, Michigan were enrolled
within 2 years after diagnosis between 1 July 2001 and 31
December 2004 for an observational prostate cancer case–
control study. Of the 637 cases, 429 (67%) underwent
radical prostatectomy and were followed from the date of
surgery forward using electronic medical records to
retrieve all prostate speciﬁc antigen (PSA) test results. We
excluded the 20 cases that had no follow-up or only one
PSA test after surgery and 14 men who also underwent
hormone treatment. One case was excluded because of
missing tumor grade information. The remaining 394 men
comprised the analytic study sample, which had data on
4,459 follow-up PSA test results, ranging from 2 to 54 tests
and a median of ten PSA tests per subject. All protocols
used in this study were reviewed and approved by the
Henry Ford Hospital Institutional Review Board and all
study participants provided informed consent.
Genotyping
Standard venipuncture was used to collect blood samples
from all study participants in tubes with EDTA as an
anticoagulant. Genomic DNA was extracted from buffy
coats using QIAmp DNA Blood kit (Qiagen Inc., Valencia,
CA). All puriﬁed DNA samples were diluted to a constant
DNA concentration in 10 mmol/L Tris, 1 mmol/L EDTA
buffer (pH 8).
The GSTP1 Ile105Val (rs947894) polymorphism was
detected using the Invader assay with reagents developed
by Third Wave Technologies, Inc. (Madison, WI), which
uses primers 50-ACC CCA GGG CTC TAT GGG AA-30
and 50-TGA GGG CAC AAG AAG CCC CT-30 followed
by digestion with Alw261. Separation of PCR products,
either a 176 bp (GSTP1 Ile) or 91 and 85 bp (GSTP Val),
was done on a 3.5% agarose gel.
The full deletion of GSTM1 and GSTT1 was detected
by PCR with b-globin as an internal control by the method
of Arand et al. with modiﬁcations [16, 17]. Primers used
were 50-GAACTCCCTGAAAAGCTAAAGC-30 and 50-G
TTGGGCTCAAATATACGGTGG-30 for GSTM1 or 50-T
TCCTTACTGGTCCTCACATCT-30 and 50-TCACCGGA
TCATGGCCAGCA-30 for GSTT1 and 50-GAAGAGCC
AAGGACAGGTAC-30 and 50-CAACTTCATCCACGTT
CACC-30 for b-globin. DNA (50 ng) was ampliﬁed in a
reaction volume of 25 ll with 10 pmol of each of the
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123primers, 1.5 mM MgCl2 and 1.5 U AmpliTaq Gold DNA
polymerase. Cycling conditions were 10 min at 94C,
followed by 35 cycles (GSTM1) or 30 cycles (GSTT1) of
94C for 1 min, 62C for 1 min, 72C for 1 min and a ﬁnal
extension at 72C for 5 min. PCR products were separated
on a 2% agarose gel and GSTM1 identiﬁed by a 215 bp
band, GSTT1 by a 473 bp band and b-globin by a 268 bp
band.
Statistical analysis
Hazard ratios (HRs) for prostate cancer biochemical
recurrence (BCR) by genotype status for the GSTM1-null,
GSTT1-null and GSTP1 Ile105Val polymorphisms were
estimated with a Cox proportional hazard model using
PROC PHREG in SAS v9.1 (SAS Institute, Inc., Cary,
NC). Following Freedland et al. [18] and Kupelian et al.
[19], we deﬁned a BCR event as having two consecutive
detectable (PSA[0.2 ng/mL) increasing PSA levels for
four or more weeks after surgery. Time to event was
deﬁned as the duration between the date of surgery and the
second PSA test that deﬁned the recurrence event. Patients
did not recur were censored at the last post-operative PSA
test. Differences in survival curves were tested using the
Wilcoxon rank test using PROC LIFETEST in SAS v9.1
(SAS Institute, Inc., Cary, NC). All models were adjusted
for age, race, smoking, tumor stage, tumor (Gleason score)
grade and PSA level at diagnosis. We evaluated potential
confounding by race (population stratiﬁcation) in a subset
of African-American cases (n = 146) with African ances-
try scores, which we estimated using ADMIXMAP
software (http://homepages.ed.ac.uk/pmckeigu/admixmap)
[20] and a standard panel of ancestry informative markers
(http://www.illumina.com/pages.ilmn?ID=235). We also
examined potential confounding by PAH-DNA adduct
levels in a subset of patients (N = 368) with PAH-DNA
adduct data available. We investigated whether GST
polymorphisms were associated with BCR of prostate
cancer in subgroups deﬁned by race (Caucasian, African-
American) and clinical risk factors (clinical tumor stage,
tumor grade (from biopsy Gleason score) and PSA level at
diagnosis). All reported p-values are from two-sided tests.
Results
Characteristics of the study population are shown in
Table 1. Biochemical recurrence (BCR) of prostate cancer
was experienced by 76 men (19.3%). Men with a BCR
event had an average follow-up time of 66.9 months, which
was not signiﬁcantly different from the mean follow-up
time of men not having a BCR event (61.0 months); how-
ever, for purposes of the analyses and presentation of sur-
vival data, follow-up time was censored at 60 months
(5 years). Those men that experienced BCR were more
likely to have tumors with an advanced stage (T3 or higher),
Table 1 Characteristics of 394
prostate cancer cases by
biochemical recurrence (BCR)
status following prostatectomy
surgery
a p-value from t-test or v
2 test,
as applicable
b Time from study entry to date
of last PSA test for the entire
cohort
c High-grade deﬁned as a total
Gleason score of eight or higher
or a primary Gleason score of
four or higher
d Advanced tumor stage deﬁned
as Stage 3a or higher
e Number of GSTM1 null,
GSTT1 null and GSTP1 105Val
alleles
Characteristic BCR (n = 76) No BCR (n = 318) p-value
a
Age (mean ± SE) 60.8 ± 6.0 61.0 ± 6.8 0.73
African-Americans (%) 30 (39.5%) 138 (43.4%) 0.53
Average time of follow-up/observation (months)
b 66.9 ± 24.7 61.0 ± 22.7 0.09
PSA at diagnosis (ng/ml) 10.6 ± 9.6 6.0 ± 4.3 \0.001
High tumor grade
c 35 (46.1%) 77 (24.2%) \0.001
Advanced tumor stage
d 30 (39.7%) 43 (13.5%) \0.001
Cigarette smoking status
Never 23 (33.3%) 119 (38.1%) 0.42
Former 46 (60.5%) 156 (51.7%)
Current 7 (9.2%) 33 (10.3%)
GSTM1 null 32 (42.1%) 123 (38.7%) 0.58
GSTT1 null 15 (19.7%) 67 (21.1%) 0.80
GSTP1 Ile105Val
Ile/Ile 26 (34.2%) 117 (36.8%) 0.22
Ile/Val 34 (44.7%) 159 (50.0%)
Val/Val 16 (21.1%) 42 (13.2%)
Total number of high risk genotypes (combined)
e
0 11 (14.5%) 53 (16.7%) 0.96
1 36 (47.4%) 149 (46.9%)
2 26 (32.4%) 106 (33.3%)
3 3 (4.0%) 10 (3.1%)
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123high tumor grade (total Gleason score C8 or primary
Gleason C4), and higher PSA level at diagnosis. The mean
age at diagnosis, smoking status and race were not signiﬁ-
cantly different between men with a BCR event and those
not experiencing BCR. Genotype frequencies for the
GSTM1 null, GSTT1 null and GSTP1 Ile105Val poly-
morphisms were not signiﬁcantly different between men
with and without recurrence. In addition, the number of
GST variant (risk) alleles was also not signiﬁcantly differ-
ent between the two groups.
Kaplan-Meier curves for prostate cancer BCR in the
GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms
were not signiﬁcantly different (Fig. 1a–d). For the
GSTM1 null (Fig. 1, Panel a) and GSTP1 105 Val/Val
(Fig. 1, Panel c) genotypes, BCR was higher at 2 to 3 years
of follow-up, but the survival curves tended to move
toward each other at 5 years. In models adjusted for age,
race, smoking, tumor stage, tumor grade and PSA at
baseline (Table 2), a non-statistically signiﬁcant increased
risk of BCR was observed in men with the GSTM1 null
(HR = 1.41; 95% CI 0.88–2.26; p = 0.16) and GSTT1
null (HR = 1.11; 95% CI 0.63–1.96; p = 0.72) genotypes
compared to those with GSTM1 and GSTT1 present,
respectively. Similarly, we observed no statistically sig-
niﬁcant association between the GSTP1 Ile105Val poly-
morphism and prostate cancer BCR, with the largest effect
size observed with a recessive genetic model (i.e., GSTP1
105 Val/Val versus Ile/Ile or Ile/Val: HR = 1.62; 95% CI
0.87–2.68; p = 0.14). We also examined the total number
of putative high risk (variant) GST genotypes and under an
additive model (i.e., having 1, 2, or all 3 GST variants
(GSTM1 null, GSTT1 null and/or GSTP1 105 Ile/Val or
Val/Val) versus having no GST variants (GSTM1 present,
GSTT1 present and GSTP1 105 Ile/Ile) we observed no
signiﬁcant increased BCR risk (HR = 1.15; 95% CI 0.85–
1.56; p = 0.37).
When we stratiﬁed by race (Table 2), however, we
found that the GSTT1 null genotype increased risk in
African-Americans (HR = 2.30; 95% CI = 1.01–5.18;
p = 0.04) but not in Caucasians (p-value for the
race 9 genotype interaction term (pint) = 0.02). The
GSTM1 null genotype conferred a modest, non-statistically
signiﬁcant increased risk of BCR in Caucasians
(HR = 1.61; 95% CI = 0.89–2.96; p = 0.11), but the
effect size in African-Americans was not much different
than 1.0 (HR = 1.11; 95% CI = 0.44–2.40; p = 0.95). No
signiﬁcant association was observed for either Caucasian or
African-American men with the GSTP1 105Val variant
allele under any genetic model (recessive, dominant, or
additive). Interestingly, in African-Americans, the total
number of high risk GST genotypes under an additive
genetic model was associated with an increased BCR risk
(HR = 1.89; 95% CI 1.06–3.40; p = 0.03), but this asso-
ciation was not observed in Caucasians (pint = 0.04).
We next examined potential associations between GST
polymorphisms and prostate cancer BCR by measures of
disease severity at diagnosis. Kaplan–Meier curves for
BCR for each of the three GST polymorphisms and the
Fig. 1 Kaplan–Meier survival
curves for biochemical
recurrence of prostate cancer for
GST polymorphisms: a GSTM1
null versus GSTM1 present (log
rank p = 0.4); b GSTT1 null
versus GSTT1 present (log rank
p = 0.9); c GSTP1 codon 105
Ile/Ile versus Ile/Val versus Val/
Val (log rank p = 0.2) and d
total number of GST high risk
(variant) genotypes (log rank
p = 0.9)
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123combined high risk genotypes by tumor grade are shown in
Fig. 2a–d. When stratifying by genotype, patients with
high grade tumors had increased prostate cancer BCR if
they had the GSTT1 null (Fig. 2, Panel b: Log Rank
p = 0.003) or the GSTP1 105 Ile/Val or Val/Val (Panel c:
Log Rank p = 0.003) genotypes. However, further strati-
ﬁcation by race revealed that the risk associated with the
GSTT1 null and GSTP1 105 Ile/Val or Val/Val genotypes
was even greater in African-Americans and essentially
absent in Caucasians (Table 3). More speciﬁcally, African-
Americans with high grade tumors and the GSTT1 null
genotype had nearly an eightfold increased risk of BCR
compared to African-Americans with low grade tumors and
GSTT1 present (HR = 7.82; 95% CI = 2.49–24.50;
p\0.001). In addition, African-American patients with
high grade tumors and the GSTP1 105 Ile/Val or Val/Val
genotypes had over a threefold increased risk of BCR
compared to African-Americans with low grade tumors and
the GSTP1 Ile/Ile genotype (HR = 3.68; 95% CI = 1.13–
12.04; p = 0.03). Caucasian men with high grade tumors
and the GSTM1 null genotype had nearly a threefold
increased risk of BCR compared to Caucasians with low
grade tumors and GSTM1 present (HR = 2.88; 95%
CI = 1.16–7.14; p = 0.02). Moreover, having two or three
compared to one or no high risk (variant) GST genotypes
only conferred increased BCR risk in African-Americans
with high grade tumors (HR = 4.78; 95% CI = 1.58–
14.43; p = 0.006).
We observed similar ﬁndings when examining associa-
tions for the various GST polymorphisms by clinical tumor
stage subgroups. Speciﬁcally, we found that patients with
high stage tumors had increased prostate cancer BCR if
they had the GSTT1 null (Fig. 3, Panel b: Log Rank
p\0.0001) or the GSTP1 105 Ile/Val or Val/Val (Panel c:
Log Rank p =\0.0001) genotypes. Furthermore, as shown
in Table 4, men with high stage tumors and the GSTM1
null genotype had an increased BCR risk compared to
those with low stage tumors and GSTM1 present
(HR = 3.58; 95% CI = 1.82–7.05; p\0.001); however,
stratifying by race revealed that this association only
Table 2 Risk of prostate cancer biochemical recurrence after prostatectomy associated with GST polymorphisms by race
Polymorphism Total sample
(n = 394)
Caucasians
(n = 226)
African-Americans
(n = 168)
P-value
a
GSTM1 null 1.41 (0.88–2.26); p = 0.16
(NH1 = 32; NR = 44)
b
1.61 (0.89–2.96); p = 0.11
(NH1 = 24; NR = 22)
1.11 (0.44–2.40); p = 0.95
(NH1 = 8; NR = 22)
0.62
GSTT1 null 1.11 (0.63–1.96); p = 0.72
(NH1 = 15; NR = 61)
0.55 (0.21–1.40); p = 0.20
(NH1 = 5; NR = 41)
2.30 (1.01–5.18); p = 0.04
(NH1 = 10; NR = 20)
0.02
GSTP1 Ile105Val
Co-dominant
Ile/Val vs. Ile/Ile 0.81 (0.48–1.39); p = 0.44
(NH1 = 16; NR = 34)
0.54 (0.27–1.08); p = 0.08
(NH1 = 9; NR = 17)
1.71 (0.64–4.55); p = 0.28
(NH1 = 7; NR = 17)
0.22
Val/Val vs. Ile/Ile 1.35 (0.71–2.57); p = 0.37
(NH1 = 16; NR = 26)
0.96 (0.40–2.28); p = 0.93
(NH1 = 9; NR = 20)
2.10 (0.66–6.67); p = 0.21
(NH1 = 7; NR = 6)
0.50
Recessive
Val/Val vs. Ile/Val or Ile/Ile 1.62 (0.87–2.68); p = 0.14
(NH1 = 16; NR = 60)
1.39 (0.64–3.00); p = 0.42
(NH1 = 9; NR = 37)
1.45 (0.59–3.55); p = 0.42
(NH1 = 7; NR = 23)
0.96
Dominant
Ile/Val or Val/Val vs. Ile/Ile 0.93 (0.57–1.53); p = 0.78
(NH1 = 50; NR = 26)
0.62 (0.33–1.18); p = 0.15
(NH1 = 26; NR = 20)
1.81 (0.71–4.63); p = 0.22
(NH1 = 24; NR = 6)
0.26
Additive
Ile/Val vs. Val/Val vs. Ile/Ile 1.11 (0.79–1.57); p = 0.54
(NH1 = 16; NH2 = 34; NR = 26)
0.87 (0.55–1.39); p = 0.56
(NH1 = 9; NH2 = 17; NR = 20)
1.44 (0.83–2.52); p = 0.20
(NH1 = 7; NH2 = 17; NR = 6)
0.35
Total number of high risk
GST genotypes
c
1.15 (0.85–1.56); p = 0.37
(NH1 = 3; NH2 = 26; NH3 = 36;
NR = 11)
0.92 (0.64–1.32); p = 0.65
(NH1 = 0; NH2 = 17;
NH3 = 21; NR = 8)
1.89 (1.06–3.40); p = 0.03
(NH1 = 3; NH2 = 9; NH3 = 15;
NR = 3)
0.04
Hazard ratio (HR) and the 95% conﬁdence interval (CI) adjusted for age, race, smoking, tumor stage, tumor grade and PSA at diagnosis
a p-value for race 9 genotype interaction
b Number of events in putative high risk groups (Nh1, Nh2, Nh3) versus low risk referent group (NR)
c Additive risk of having 1, 2 or 3 of the GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val genotypes versus having no variant
genotypes
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123remained signiﬁcant among Caucasians (HR = 4.89; 95%
CI = 2.10–11.43; p\0.001). African-Americans with
high stage tumors, however, had increased BCR when they
had the GSTT1 null (HR = 6.20; 95% CI = 1.63–23.58;
p = 0.008) or the GSTP1 105 Ile/Val or Val/Val
(HR = 3.94; 95% CI = 1.25–12.43) genotype compared
to African-Americans with low stage tumors and GSTT1
present or GSTP1 105 Ile/Ile, respectively. Similar to the
results with high tumor grade, only African-American
patients with high stage tumors and two or three compared
to one or no high risk (variant) GST genotypes had
increased risk of BCR (HR = 3.60; 95% CI = 1.11–11.65;
p = 0.03).
Men with more aggressive (high grade or high stage)
tumors carrying the GSTM1 null genotype had an increased
risk of BCR compared to those with less aggressive (low
grade or low stage) disease and GSTM1 present
(HR = 3.75; 95% CI = 1.85–7.61; p\0.001); however,
after stratifying by race, this association only remained
statistically signiﬁcant in Caucasians (HR = 4.26; 95%
CI = 1.73–10.48; p = 0.002) (Table 5). African-Ameri-
cans with more aggressive disease carrying the GSTT1 null
genotype had increased BCR compared to those with less
aggressive disease and GSTT1 present (HR = 5.61; 95%
CI = 1.72–18.36; p = 0.004). Furthermore, men with more
aggressive disease carrying 2–3 GST variants compared to
those with less aggressive disease carrying none or one GST
variant had an increased risk of BCR (HR = 3.00; 95%
CI = 1.55–5.78; p = 0.001), but this association was
stronger in African-Americans (HR = 5.14; 95% CI =
1.65–16.07; p = 0.005) than in Caucasians (HR = 2.29;
95% CI = 1.02–5.13; p = 0.05).
In a subset of African-American cases for which we also
had ancestry informative markers (N = 146), we addition-
ally adjusted all models for African ancestry scores (see
‘‘Methods: Statistical Analysis’’) and observed no material
differences (data not shown). Furthermore, because we
previously observed that PAH-DNA adducts in prostate
cells were associated with an increased risk of prostate
cancer BCR [21], we also performed all of the aforemen-
tioned analyses with additional adjustment for PAH-DNA
adduct levels in a subset of patients with PAH-DNA adduct
data also available (N = 368); and we observed no material
differences in any of the results presented (data not shown).
Discussion
We found that the GSTT1 null and GSTP1 105 Ile/Val and
Val/Val variant genotypes increased risk of prostate cancer
BCR in African-Americans but not Caucasians with high
grade and high stage tumors; and the GSTM1 null variant
genotype increased risk of BCR in Caucasians but not
African-Americans with high grade and high stage tumors.
Effect sizes (HRs) in African-Americans were markedly
smaller for the GSTP1 polymorphism (3.68 and 3.94 for
high grade and high stage tumors, respectively) compared
to those observed for the GSTT1 null polymorphism (7.82
Fig. 2 Kaplan–Meier survival
curves for biochemical
recurrence of prostate cancer for
GST polymorphisms in high
versus low tumor grade:
a GSTM1 null versus GSTM1
present (log rank p = 0.0002);
b GSTT1 null versus GSTT1
present (log rank p = 0.0001);
c GSTP1 codon 105 Ile/Ile and
Ile/Val versus Val/Val (log rank
p\0.00001) and d total
number of GST high risk
(variant) genotypes (log rank
p = 0.0001)
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123and 6.20 for high grade and high stage tumors,
respectively).
In the only prior report examining the potential associ-
ation between GST polymorphisms and prostate cancer
biochemical recurrence, Agalliu et al. [14] found that in
Caucasian men the GSTM1 null genotype increased the
risk prostate cancer recurrence by 56%, but this was not
statistically signiﬁcant. Our ﬁndings are consistent with
these prior results in that we observed a modest (61%) but
non-statistically signiﬁcant increased risk of BCR with the
GSTM1 null genotype in our Caucasian patient population.
However, we did observe a signiﬁcant increased risk with
the GSTM1 null genotype in Caucasian patients with high
grade and advanced (high) stage disease. Agalliu et al. [14]
also reported that neither the GSTT1 null or GSTP1
Ile105Val polymorphisms were associated with recurrence
or mortality, which is consistent with our ﬁndings among
Caucasians but not in African-Americans, where we
observed a signiﬁcant association between the GSTT1 null
genotype and BCR, which was markedly increased among
African-Americans with high grade and advanced stage
disease. Importantly, their study population comprised only
a small percentage of patients with high grade tumors (total
Gleason score of eight or greater), which may help explain
the differences in our results. Furthermore, the Agalliu
et al. population was comprised predominantly of Cauca-
sians (95%), which limited their ability to potentially detect
the differences we observed when stratifying by race and
tumor grade, particularly since African-American men
generally present with more advanced disease [2] and have
higher rates of recurrence than Caucasian men [6]. More-
over, our study population was restricted to those who
treated with radical prostatectomy alone, whereas the
Agalliu et al. [14] study population included men who
underwent androgen deprivation therapy (ADT) (8.4%
with BCR, 2.5% without BCR), ADT and radiation (21.0%
with BCR, 16.7% without BCR), and a few men who did
not undergo any treatment (3.5% with BCR, 6.2% without
BCR) for prostate cancer. Differences in treatment regimes
could potentially affect the association between GST
polymorphisms and biochemical recurrence due to the
numerous functions of GSTs including metabolism of
steroid hormones and detoxiﬁcation of carcinogenic
metabolites [7]. When Agalliu et al. [14] restricted their
analysis to only those treated with radical prostatectomy,
they found an even higher risk of recurrence with the
GSTM1 null polymorphism, but this result was not statis-
tically signiﬁcant.
Although a recent meta-analysis suggests polymor-
phisms in GSTM1 null, GSTT1 null and GSTP1 Ile105Val
are unlikely to be major determinants of prostate cancer
incidence [12], our results suggest that GST polymorphisms
may play a greater role in recurrence of advanced prostate
cancer and effects may differ by race. Speciﬁcally, we
found that the GSTT1 null and GSTP1 Ile105Val poly-
morphisms were associated with increased BCR in African-
Fig. 3 Kaplan–Meier survival
curves for biochemical
recurrence of prostate cancer for
GST polymorphisms in high
versus low tumor stage:
a GSTM1 null versus GSTM1
present (log rank p\0.0001);
b GSTT1 null versus GSTT1
present (log rank p\0.0001);
c GSTP1 codon 105 Ile/Ile and
Ile/Val versus Val/Val (log rank
p\0.0001) and d total number
of GST high risk (variant)
genotypes (log rank
p\0.0001)
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123American men but not Caucasian men with high grade and
high stage tumors and that the GSTM1 null polymorphism
was associated with BCR in Caucasian men but not African-
American men with high grade and high stage tumors.
Although the total number of high risk (variant) GST
genotypes increased BCR risk almost twofold in African-
Americans, we did not observe a signiﬁcant effect with
having increasing numbers of GST variants in Caucasians.
We hypothesize that the potential role of the GSTP1 poly-
morphism is complicated by the consistent ﬁnding that the
GSTP1 promoter region CpG islands are hypermethylated,
leading to inactivation of GSTP1 in prostate tumor cells
[22], which may serve as an indicator of biochemical
recurrence after radical prostatectomy [23]. Perhaps, the
silencing of GSTP1 in prostate cancer speaks to an even
greater role for the GSTM1 null and GSTT1 null poly-
morphisms in prostate cancer progression, since the partial
or complete lack of GSTP1 function would require that
GSTM1 or GSTT1 serve as substitutes where there is
overlap in their substrate speciﬁcities [7]. Although, why
GSTM1 might be more biologically important in Cauca-
sians and GSTT1 in African-Americans is unclear. Differ-
ences in patterns of exposure may play a role. For example,
we [13] and others [24] have observed interactions between
the GSTM1 null polymorphism and smoking in Caucasians,
but larger studies are needed to better understanding of
these and other possible gene–environment interactions.
Strengths of our study include the use of patients who
only underwent surgery (radical prostatectomy) for treat-
ment, which prevented confounding by treatment and
enabled a uniform deﬁnition of disease recurrence. Our
study population also had a fairly large representation of
African-American patients (42.6%). However, our sample
size diminished considerably after further stratifying by
genotype and clinical measures. Furthermore, due to the
exploratory nature of our analyses, we did not correct for
multiple statistical tests. Therefore, our results should be
interpreted with caution and require validation in a larger
independent study population.
In summary, we found that the GSTT1 null genotype
increased risk of BCR in African-American men with
prostate cancer, particularly those patients with high grade
and high stage tumors. In Caucasians with high grade and
high stage tumors, the GSTM1 null genotype increased risk
of BCR. Overall, the GST polymorphisms were more
strongly associated with BCR risk in African-Americans,
suggesting GST-targeted therapeutics may have their
greatest impact on treatment of advanced prostate cancers
in African-Americans.
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